Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Cost-Benefit Analysis | 62 | 2016 | 5265 | 1.760 |
Why?
|
Health Expenditures | 17 | 2018 | 2270 | 1.730 |
Why?
|
Health Care Costs | 18 | 2014 | 3164 | 1.170 |
Why?
|
Medicare | 14 | 2018 | 5791 | 1.120 |
Why?
|
Comparative Effectiveness Research | 4 | 2011 | 689 | 1.090 |
Why?
|
Technology Assessment, Biomedical | 7 | 2007 | 302 | 1.080 |
Why?
|
Quality-Adjusted Life Years | 29 | 2016 | 1626 | 0.810 |
Why?
|
Natural Language Processing | 4 | 2009 | 953 | 0.760 |
Why?
|
Biomedical Technology | 5 | 2006 | 219 | 0.760 |
Why?
|
Health Services Research | 8 | 2009 | 1840 | 0.740 |
Why?
|
Diffusion of Innovation | 4 | 2016 | 715 | 0.700 |
Why?
|
Colectomy | 2 | 2012 | 650 | 0.610 |
Why?
|
Markov Chains | 15 | 2016 | 985 | 0.580 |
Why?
|
Cost Control | 4 | 2013 | 626 | 0.560 |
Why?
|
Economic Competition | 2 | 2016 | 237 | 0.550 |
Why?
|
Defibrillators, Implantable | 6 | 2010 | 1405 | 0.540 |
Why?
|
Mass Screening | 18 | 2006 | 5209 | 0.530 |
Why?
|
Health Policy | 10 | 2016 | 2649 | 0.520 |
Why?
|
Information Storage and Retrieval | 3 | 2009 | 835 | 0.500 |
Why?
|
United States | 63 | 2018 | 67905 | 0.500 |
Why?
|
Vaginal Smears | 4 | 2001 | 499 | 0.480 |
Why?
|
Hypercholesterolemia | 7 | 2000 | 1160 | 0.480 |
Why?
|
Industry | 2 | 2006 | 367 | 0.470 |
Why?
|
Cholesterol | 8 | 2000 | 2866 | 0.470 |
Why?
|
Sulfonylurea Compounds | 2 | 2011 | 191 | 0.460 |
Why?
|
Multimedia | 5 | 2005 | 72 | 0.460 |
Why?
|
Randomized Controlled Trials as Topic | 11 | 2016 | 9596 | 0.450 |
Why?
|
Evidence-Based Medicine | 6 | 2005 | 3683 | 0.450 |
Why?
|
Utilization Review | 2 | 2005 | 401 | 0.440 |
Why?
|
Drug Industry | 3 | 2009 | 902 | 0.440 |
Why?
|
Glucagon-Like Peptide 1 | 2 | 2011 | 315 | 0.430 |
Why?
|
Drug Approval | 3 | 2009 | 899 | 0.430 |
Why?
|
Gaucher Disease | 7 | 1998 | 113 | 0.430 |
Why?
|
Death, Sudden, Cardiac | 3 | 2018 | 1502 | 0.420 |
Why?
|
Reimbursement, Incentive | 4 | 2013 | 520 | 0.410 |
Why?
|
Mesalamine | 1 | 2011 | 135 | 0.410 |
Why?
|
Colonic Pouches | 1 | 2012 | 116 | 0.410 |
Why?
|
Kyphoplasty | 1 | 2011 | 45 | 0.400 |
Why?
|
Coronary Disease | 14 | 2000 | 6150 | 0.400 |
Why?
|
Health Care Reform | 5 | 2016 | 1249 | 0.390 |
Why?
|
Azathioprine | 1 | 2011 | 345 | 0.390 |
Why?
|
Technology, High-Cost | 1 | 2010 | 32 | 0.390 |
Why?
|
Decision Making | 4 | 2011 | 3846 | 0.390 |
Why?
|
Colitis, Ulcerative | 2 | 2012 | 1824 | 0.380 |
Why?
|
Organizational Policy | 5 | 2008 | 439 | 0.380 |
Why?
|
Vertebroplasty | 1 | 2011 | 75 | 0.380 |
Why?
|
Androgen Antagonists | 3 | 2012 | 1285 | 0.380 |
Why?
|
Low Back Pain | 1 | 2018 | 934 | 0.380 |
Why?
|
Private Sector | 3 | 2013 | 390 | 0.370 |
Why?
|
Academies and Institutes | 1 | 2011 | 294 | 0.370 |
Why?
|
Health Services | 3 | 2013 | 742 | 0.360 |
Why?
|
Watchful Waiting | 2 | 2012 | 451 | 0.360 |
Why?
|
Osteoporosis | 2 | 2011 | 1567 | 0.360 |
Why?
|
Insurance Coverage | 4 | 2008 | 1863 | 0.360 |
Why?
|
Capsule Endoscopy | 1 | 2009 | 90 | 0.350 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2012 | 791 | 0.350 |
Why?
|
Decision Support Techniques | 16 | 2014 | 2032 | 0.340 |
Why?
|
Glucosylceramidase | 4 | 1994 | 129 | 0.340 |
Why?
|
Myocardial Infarction | 10 | 2014 | 11401 | 0.340 |
Why?
|
Insurance Claim Reporting | 2 | 2008 | 169 | 0.330 |
Why?
|
Fast Foods | 1 | 2010 | 173 | 0.330 |
Why?
|
Hypoglycemic Agents | 7 | 2014 | 2775 | 0.330 |
Why?
|
Taxes | 1 | 2010 | 206 | 0.330 |
Why?
|
Tomography | 1 | 2009 | 361 | 0.320 |
Why?
|
Preimplantation Diagnosis | 1 | 2009 | 132 | 0.320 |
Why?
|
Device Approval | 1 | 2010 | 197 | 0.320 |
Why?
|
Equipment and Supplies | 2 | 2010 | 297 | 0.320 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 1999 | 326 | 0.320 |
Why?
|
Decision Making, Organizational | 2 | 2004 | 134 | 0.310 |
Why?
|
Humans | 136 | 2018 | 715777 | 0.300 |
Why?
|
Cystic Fibrosis | 3 | 2009 | 1133 | 0.300 |
Why?
|
Prostatectomy | 2 | 2012 | 1796 | 0.300 |
Why?
|
Sodium, Dietary | 1 | 2010 | 415 | 0.290 |
Why?
|
Pattern Recognition, Automated | 2 | 2009 | 1019 | 0.290 |
Why?
|
Government Regulation | 2 | 2010 | 546 | 0.280 |
Why?
|
Nutrition Policy | 1 | 2010 | 472 | 0.280 |
Why?
|
Delivery of Health Care | 4 | 2016 | 4881 | 0.280 |
Why?
|
Alendronate | 1 | 2006 | 174 | 0.270 |
Why?
|
Models, Econometric | 4 | 2011 | 220 | 0.260 |
Why?
|
Long-Term Care | 2 | 2004 | 593 | 0.260 |
Why?
|
Efficiency | 2 | 2008 | 491 | 0.260 |
Why?
|
Terminally Ill | 1 | 2007 | 245 | 0.260 |
Why?
|
Diabetes Mellitus, Type 2 | 6 | 2014 | 11090 | 0.260 |
Why?
|
Pharmacogenetics | 1 | 2009 | 699 | 0.260 |
Why?
|
Insurance, Health | 4 | 2008 | 2497 | 0.260 |
Why?
|
Uterine Cervical Neoplasms | 4 | 2001 | 1974 | 0.260 |
Why?
|
Costs and Cost Analysis | 13 | 2010 | 1669 | 0.260 |
Why?
|
Spinal Fractures | 1 | 2011 | 691 | 0.250 |
Why?
|
Teriparatide | 1 | 2006 | 224 | 0.250 |
Why?
|
Antibodies, Monoclonal | 3 | 2012 | 9548 | 0.250 |
Why?
|
Terminal Care | 2 | 2007 | 1641 | 0.250 |
Why?
|
Insurance Claim Review | 2 | 2008 | 750 | 0.250 |
Why?
|
Intestine, Small | 1 | 2009 | 1221 | 0.240 |
Why?
|
Protein C | 1 | 2003 | 151 | 0.240 |
Why?
|
Transcutaneous Electric Nerve Stimulation | 1 | 2004 | 148 | 0.230 |
Why?
|
Heart Arrest | 2 | 2003 | 1374 | 0.230 |
Why?
|
Activities of Daily Living | 4 | 2008 | 2316 | 0.230 |
Why?
|
Disease | 1 | 2008 | 705 | 0.230 |
Why?
|
Monte Carlo Method | 5 | 2014 | 1306 | 0.220 |
Why?
|
Prostatic Neoplasms | 4 | 2012 | 10605 | 0.220 |
Why?
|
Aged | 48 | 2018 | 162448 | 0.220 |
Why?
|
Infertility, Female | 1 | 2008 | 763 | 0.220 |
Why?
|
Tibial Fractures | 1 | 2004 | 245 | 0.220 |
Why?
|
Heparin | 2 | 1999 | 1620 | 0.210 |
Why?
|
Sensitivity and Specificity | 20 | 2010 | 14902 | 0.210 |
Why?
|
Reimbursement Mechanisms | 1 | 2007 | 658 | 0.210 |
Why?
|
Drug Costs | 3 | 2013 | 1170 | 0.210 |
Why?
|
Orphan Drug Production | 2 | 1992 | 67 | 0.210 |
Why?
|
Quality of Life | 11 | 2012 | 11721 | 0.210 |
Why?
|
Blood Glucose | 4 | 2014 | 6259 | 0.210 |
Why?
|
Orchiectomy | 2 | 2000 | 453 | 0.210 |
Why?
|
Research Support as Topic | 3 | 2011 | 725 | 0.210 |
Why?
|
Terminology as Topic | 1 | 2008 | 1612 | 0.200 |
Why?
|
Patient-Centered Care | 1 | 2011 | 1460 | 0.200 |
Why?
|
Angioplasty | 2 | 2014 | 374 | 0.200 |
Why?
|
Aircraft | 1 | 2001 | 115 | 0.200 |
Why?
|
Laparoscopy | 2 | 2011 | 1980 | 0.200 |
Why?
|
Diethylstilbestrol | 1 | 2000 | 92 | 0.200 |
Why?
|
Streptococcus agalactiae | 1 | 2002 | 373 | 0.200 |
Why?
|
Endometriosis | 1 | 2008 | 803 | 0.200 |
Why?
|
Diagnostic Techniques and Procedures | 1 | 2002 | 203 | 0.200 |
Why?
|
Drug Discovery | 1 | 2009 | 1060 | 0.200 |
Why?
|
Financing, Personal | 2 | 2013 | 313 | 0.200 |
Why?
|
Influenza Vaccines | 3 | 2014 | 689 | 0.200 |
Why?
|
Practice Guidelines as Topic | 5 | 2005 | 7446 | 0.190 |
Why?
|
California | 8 | 2008 | 1396 | 0.190 |
Why?
|
Pharmaceutical Preparations | 1 | 2009 | 1042 | 0.190 |
Why?
|
Thiazolidinediones | 2 | 2014 | 484 | 0.190 |
Why?
|
Influenza, Human | 4 | 2014 | 1388 | 0.190 |
Why?
|
Body Weight | 1 | 2011 | 4688 | 0.190 |
Why?
|
Venous Thrombosis | 2 | 1999 | 1216 | 0.190 |
Why?
|
Models, Economic | 3 | 2013 | 719 | 0.190 |
Why?
|
Intensive Care Units | 3 | 2008 | 3451 | 0.180 |
Why?
|
Cataract Extraction | 1 | 2003 | 457 | 0.170 |
Why?
|
Managed Care Programs | 1 | 2004 | 985 | 0.170 |
Why?
|
Biological Products | 1 | 2007 | 838 | 0.170 |
Why?
|
Bone Density Conservation Agents | 1 | 2006 | 785 | 0.170 |
Why?
|
Ultraviolet Therapy | 1 | 1998 | 81 | 0.170 |
Why?
|
Mass Vaccination | 2 | 2009 | 108 | 0.170 |
Why?
|
Anticoagulants | 4 | 2016 | 4375 | 0.170 |
Why?
|
Electric Countershock | 1 | 2001 | 515 | 0.170 |
Why?
|
Research | 3 | 2011 | 2016 | 0.170 |
Why?
|
Caregivers | 2 | 2011 | 1925 | 0.170 |
Why?
|
Streptococcal Infections | 1 | 2002 | 645 | 0.160 |
Why?
|
Pregnancy Outcome | 1 | 2008 | 2719 | 0.160 |
Why?
|
Female | 61 | 2018 | 377204 | 0.160 |
Why?
|
Health Care Rationing | 1 | 2001 | 457 | 0.160 |
Why?
|
Healthcare Disparities | 1 | 2013 | 3035 | 0.160 |
Why?
|
Male | 57 | 2018 | 350324 | 0.160 |
Why?
|
Osteogenesis | 1 | 2004 | 1277 | 0.160 |
Why?
|
Age Factors | 9 | 2018 | 18784 | 0.160 |
Why?
|
Life Expectancy | 6 | 2013 | 1143 | 0.150 |
Why?
|
Receptor, erbB-2 | 1 | 2007 | 2313 | 0.150 |
Why?
|
Interviews as Topic | 5 | 2005 | 2596 | 0.150 |
Why?
|
Crohn Disease | 1 | 2009 | 2256 | 0.150 |
Why?
|
Artificial Intelligence | 1 | 2008 | 1744 | 0.150 |
Why?
|
State Medicine | 2 | 2008 | 206 | 0.150 |
Why?
|
Government Agencies | 1 | 1996 | 163 | 0.150 |
Why?
|
Attitude to Health | 3 | 2008 | 2110 | 0.150 |
Why?
|
Decision Trees | 6 | 2016 | 523 | 0.150 |
Why?
|
Quality Assurance, Health Care | 4 | 2008 | 2260 | 0.140 |
Why?
|
Disease Outbreaks | 3 | 2010 | 1741 | 0.140 |
Why?
|
Stroke | 5 | 2016 | 9505 | 0.140 |
Why?
|
Survival Analysis | 7 | 2007 | 10499 | 0.140 |
Why?
|
Financing, Government | 2 | 2009 | 485 | 0.140 |
Why?
|
Publishing | 1 | 2002 | 805 | 0.130 |
Why?
|
Geriatric Assessment | 5 | 2008 | 1312 | 0.130 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2000 | 1536 | 0.130 |
Why?
|
Dermatologic Agents | 1 | 1998 | 298 | 0.130 |
Why?
|
Medical Informatics | 1 | 2002 | 737 | 0.130 |
Why?
|
Polymerase Chain Reaction | 2 | 2002 | 6274 | 0.130 |
Why?
|
Quality of Health Care | 3 | 2010 | 4282 | 0.130 |
Why?
|
Software | 5 | 2008 | 4396 | 0.130 |
Why?
|
Recombinant Proteins | 2 | 2007 | 6803 | 0.130 |
Why?
|
Hyperlipidemias | 2 | 2002 | 803 | 0.130 |
Why?
|
Hospitals, Veterans | 1 | 1996 | 403 | 0.130 |
Why?
|
Treatment Outcome | 18 | 2014 | 62004 | 0.120 |
Why?
|
Visual Acuity | 1 | 2003 | 2490 | 0.120 |
Why?
|
Socioeconomic Factors | 4 | 2018 | 7757 | 0.120 |
Why?
|
Academic Medical Centers | 1 | 2004 | 2789 | 0.120 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1999 | 1181 | 0.120 |
Why?
|
United States Department of Veterans Affairs | 2 | 2006 | 857 | 0.120 |
Why?
|
Health Services for the Aged | 2 | 2004 | 263 | 0.120 |
Why?
|
Hypolipidemic Agents | 1 | 1998 | 617 | 0.120 |
Why?
|
Coronary Angiography | 2 | 2010 | 4410 | 0.120 |
Why?
|
Renal Dialysis | 3 | 2008 | 1744 | 0.120 |
Why?
|
Brachytherapy | 2 | 2012 | 1282 | 0.120 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 2280 | 0.120 |
Why?
|
Middle Aged | 33 | 2013 | 214639 | 0.120 |
Why?
|
Anticholesteremic Agents | 1 | 2000 | 960 | 0.120 |
Why?
|
Survivors | 1 | 2003 | 2171 | 0.110 |
Why?
|
Hospital Costs | 3 | 2007 | 976 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 2 | 2002 | 1185 | 0.110 |
Why?
|
Atrial Appendage | 1 | 2016 | 257 | 0.110 |
Why?
|
Attitude to Computers | 2 | 2005 | 199 | 0.110 |
Why?
|
Risk Factors | 20 | 2018 | 70866 | 0.110 |
Why?
|
Public Policy | 1 | 1996 | 556 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2013 | 3149 | 0.110 |
Why?
|
Prenatal Diagnosis | 2 | 1991 | 1179 | 0.110 |
Why?
|
Hospitals | 1 | 2005 | 3375 | 0.110 |
Why?
|
Cost of Illness | 4 | 2012 | 1840 | 0.110 |
Why?
|
Human Growth Hormone | 2 | 2008 | 701 | 0.110 |
Why?
|
Methotrexate | 1 | 1998 | 1725 | 0.110 |
Why?
|
Rhabdomyolysis | 1 | 2013 | 157 | 0.110 |
Why?
|
American Recovery and Reinvestment Act | 1 | 2011 | 66 | 0.110 |
Why?
|
Health Status Indicators | 3 | 2008 | 986 | 0.100 |
Why?
|
Patient Satisfaction | 3 | 2011 | 3398 | 0.100 |
Why?
|
Choice Behavior | 1 | 1997 | 794 | 0.100 |
Why?
|
Geography | 1 | 2013 | 691 | 0.100 |
Why?
|
Genetic Testing | 3 | 2006 | 3350 | 0.100 |
Why?
|
Pravastatin | 1 | 2013 | 390 | 0.100 |
Why?
|
Coronary Artery Bypass | 3 | 2014 | 2397 | 0.100 |
Why?
|
Health Services Accessibility | 2 | 2005 | 5038 | 0.100 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2002 | 2034 | 0.100 |
Why?
|
beta-Alanine | 1 | 2010 | 76 | 0.100 |
Why?
|
Aged, 80 and over | 13 | 2018 | 58323 | 0.100 |
Why?
|
Combined Modality Therapy | 2 | 2014 | 8890 | 0.100 |
Why?
|
Life Support Care | 1 | 2011 | 220 | 0.100 |
Why?
|
Psoriasis | 1 | 1998 | 974 | 0.100 |
Why?
|
Adult | 29 | 2010 | 212266 | 0.090 |
Why?
|
Carotid Stenosis | 1 | 1997 | 812 | 0.090 |
Why?
|
Nephrons | 1 | 2011 | 197 | 0.090 |
Why?
|
Cerebrovascular Disorders | 1 | 1997 | 1507 | 0.090 |
Why?
|
United States Food and Drug Administration | 2 | 2010 | 1778 | 0.090 |
Why?
|
Jurisprudence | 1 | 2010 | 118 | 0.090 |
Why?
|
Sepsis | 1 | 2003 | 2465 | 0.090 |
Why?
|
Sex Factors | 5 | 2018 | 10666 | 0.090 |
Why?
|
Expressed Emotion | 1 | 2010 | 96 | 0.090 |
Why?
|
Eligibility Determination | 1 | 2013 | 386 | 0.090 |
Why?
|
Equipment Failure | 2 | 2010 | 579 | 0.090 |
Why?
|
African Americans | 1 | 2005 | 5003 | 0.090 |
Why?
|
Breast Neoplasms | 2 | 2007 | 20062 | 0.090 |
Why?
|
Subject Headings | 1 | 2008 | 20 | 0.090 |
Why?
|
Public Health | 1 | 2002 | 2430 | 0.090 |
Why?
|
Therapeutic Equivalency | 1 | 2009 | 158 | 0.090 |
Why?
|
Risk | 3 | 2018 | 9801 | 0.090 |
Why?
|
Influenza A Virus, H5N1 Subtype | 1 | 2009 | 114 | 0.090 |
Why?
|
Electrocardiography | 3 | 1999 | 6386 | 0.090 |
Why?
|
Antihypertensive Agents | 2 | 1998 | 2058 | 0.090 |
Why?
|
Physicians | 2 | 2004 | 4375 | 0.090 |
Why?
|
Object Attachment | 1 | 2011 | 305 | 0.090 |
Why?
|
Diabetes Complications | 2 | 2014 | 1397 | 0.090 |
Why?
|
Probability | 3 | 2003 | 2487 | 0.090 |
Why?
|
Residence Characteristics | 1 | 2018 | 2003 | 0.090 |
Why?
|
Diet, Sodium-Restricted | 1 | 2010 | 272 | 0.080 |
Why?
|
Psychometrics | 1 | 1998 | 2971 | 0.080 |
Why?
|
Pregnancy, Multiple | 1 | 2009 | 219 | 0.080 |
Why?
|
Drug Resistance, Microbial | 2 | 1989 | 877 | 0.080 |
Why?
|
Observation | 1 | 2010 | 315 | 0.080 |
Why?
|
Standard of Care | 1 | 2011 | 522 | 0.080 |
Why?
|
Hypoglycemia | 2 | 2010 | 813 | 0.080 |
Why?
|
Twins | 1 | 2009 | 354 | 0.080 |
Why?
|
Athletic Performance | 1 | 2008 | 92 | 0.080 |
Why?
|
Coronary Artery Disease | 3 | 2014 | 6289 | 0.080 |
Why?
|
Gastrointestinal Agents | 1 | 2012 | 493 | 0.080 |
Why?
|
Multivariate Analysis | 5 | 2005 | 12480 | 0.080 |
Why?
|
Exercise Test | 2 | 1999 | 2110 | 0.080 |
Why?
|
Drugs, Generic | 2 | 2014 | 520 | 0.080 |
Why?
|
Decision Making, Computer-Assisted | 2 | 1998 | 162 | 0.070 |
Why?
|
Logistic Models | 4 | 2010 | 13618 | 0.070 |
Why?
|
Warfarin | 2 | 2016 | 1476 | 0.070 |
Why?
|
Forecasting | 3 | 2011 | 2956 | 0.070 |
Why?
|
Smoking Cessation | 1 | 1998 | 2030 | 0.070 |
Why?
|
Echocardiography | 1 | 1999 | 5044 | 0.070 |
Why?
|
Canada | 2 | 2008 | 1967 | 0.070 |
Why?
|
Pregnancy Rate | 1 | 2009 | 599 | 0.070 |
Why?
|
Computer Literacy | 2 | 2005 | 43 | 0.070 |
Why?
|
Kidney Failure, Chronic | 3 | 2013 | 2548 | 0.070 |
Why?
|
Blastocyst | 1 | 2009 | 433 | 0.070 |
Why?
|
Hospitalization | 4 | 2013 | 9745 | 0.070 |
Why?
|
Health Services Needs and Demand | 2 | 2004 | 1437 | 0.070 |
Why?
|
Public Sector | 1 | 2007 | 266 | 0.070 |
Why?
|
Evaluation Studies as Topic | 2 | 2007 | 1738 | 0.070 |
Why?
|
Anthrax Vaccines | 1 | 2005 | 14 | 0.070 |
Why?
|
Exercise | 4 | 2008 | 5427 | 0.070 |
Why?
|
Atrial Fibrillation | 2 | 2016 | 4562 | 0.070 |
Why?
|
Heart Diseases | 3 | 2002 | 2755 | 0.070 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2009 | 472 | 0.070 |
Why?
|
Clinical Trials as Topic | 5 | 2014 | 7960 | 0.070 |
Why?
|
Incidental Findings | 1 | 2010 | 676 | 0.070 |
Why?
|
Nephrectomy | 1 | 2011 | 1004 | 0.070 |
Why?
|
Benzimidazoles | 1 | 2010 | 877 | 0.070 |
Why?
|
Ischemic Attack, Transient | 1 | 2010 | 907 | 0.070 |
Why?
|
Disease Progression | 4 | 2013 | 13215 | 0.070 |
Why?
|
Abortion, Spontaneous | 1 | 2009 | 475 | 0.070 |
Why?
|
Geriatric Nursing | 1 | 2005 | 39 | 0.070 |
Why?
|
Algorithms | 4 | 2009 | 13758 | 0.070 |
Why?
|
Anthrax | 1 | 2005 | 101 | 0.070 |
Why?
|
Clinical Protocols | 1 | 1991 | 1473 | 0.060 |
Why?
|
Recurrence | 4 | 2000 | 8240 | 0.060 |
Why?
|
Computer Simulation | 2 | 2010 | 6105 | 0.060 |
Why?
|
Health Facility Merger | 1 | 2004 | 48 | 0.060 |
Why?
|
Models, Cardiovascular | 1 | 2010 | 1002 | 0.060 |
Why?
|
Direct Service Costs | 2 | 2014 | 64 | 0.060 |
Why?
|
Bioterrorism | 1 | 2005 | 149 | 0.060 |
Why?
|
Regression Analysis | 2 | 2010 | 6495 | 0.060 |
Why?
|
Rate Setting and Review | 1 | 2004 | 41 | 0.060 |
Why?
|
Double-Blind Method | 3 | 2011 | 11945 | 0.060 |
Why?
|
Adjuvants, Immunologic | 1 | 2009 | 975 | 0.060 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2009 | 622 | 0.060 |
Why?
|
Economics | 1 | 2004 | 148 | 0.060 |
Why?
|
Diagnostic Imaging | 1 | 2018 | 3494 | 0.060 |
Why?
|
Physician Executives | 1 | 2004 | 136 | 0.060 |
Why?
|
Antipsychotic Agents | 1 | 1997 | 3062 | 0.060 |
Why?
|
Capitation Fee | 1 | 2004 | 117 | 0.060 |
Why?
|
Japan | 1 | 2008 | 1341 | 0.060 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2000 | 1191 | 0.060 |
Why?
|
Cardiovascular Diseases | 1 | 2009 | 14438 | 0.060 |
Why?
|
Hypertension | 4 | 2013 | 8270 | 0.060 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2008 | 498 | 0.060 |
Why?
|
Commerce | 1 | 2009 | 602 | 0.060 |
Why?
|
Time Factors | 6 | 2013 | 40875 | 0.060 |
Why?
|
Patient Care | 1 | 2009 | 620 | 0.060 |
Why?
|
APACHE | 1 | 2003 | 270 | 0.060 |
Why?
|
Models, Theoretical | 3 | 2014 | 3580 | 0.060 |
Why?
|
Boronic Acids | 1 | 2007 | 971 | 0.060 |
Why?
|
Drug Administration Schedule | 2 | 2007 | 5031 | 0.060 |
Why?
|
Pregnancy | 4 | 2009 | 27398 | 0.060 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2013 | 1484 | 0.060 |
Why?
|
Genes, BRCA2 | 1 | 2006 | 592 | 0.060 |
Why?
|
Cohort Studies | 5 | 2007 | 40029 | 0.060 |
Why?
|
New York City | 1 | 2004 | 663 | 0.060 |
Why?
|
Heterozygote | 1 | 2009 | 2794 | 0.060 |
Why?
|
Fee-for-Service Plans | 2 | 2004 | 652 | 0.050 |
Why?
|
National Institutes of Health (U.S.) | 3 | 1996 | 763 | 0.050 |
Why?
|
Developed Countries | 1 | 2004 | 409 | 0.050 |
Why?
|
Genes, BRCA1 | 1 | 2006 | 760 | 0.050 |
Why?
|
Myocardial Revascularization | 2 | 2003 | 847 | 0.050 |
Why?
|
Affect | 1 | 2010 | 1494 | 0.050 |
Why?
|
Social Responsibility | 1 | 2005 | 393 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 2 | 2010 | 20356 | 0.050 |
Why?
|
Mortality | 3 | 1999 | 2837 | 0.050 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2011 | 1167 | 0.050 |
Why?
|
Pyrazines | 1 | 2007 | 1246 | 0.050 |
Why?
|
Reproducibility of Results | 7 | 2005 | 19537 | 0.050 |
Why?
|
Aortic Valve Stenosis | 1 | 2013 | 1844 | 0.050 |
Why?
|
Patient Selection | 2 | 2013 | 4293 | 0.050 |
Why?
|
Fertilization in Vitro | 1 | 2009 | 1255 | 0.050 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2014 | 3014 | 0.050 |
Why?
|
Europe | 1 | 2008 | 3343 | 0.050 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6552 | 0.050 |
Why?
|
Bacterial Infections | 1 | 1989 | 1425 | 0.050 |
Why?
|
Acute Coronary Syndrome | 1 | 2014 | 2263 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2010 | 2124 | 0.050 |
Why?
|
Cross Infection | 1 | 1989 | 1409 | 0.050 |
Why?
|
Bacteria | 2 | 1989 | 2115 | 0.050 |
Why?
|
Medicare Part C | 1 | 2004 | 251 | 0.050 |
Why?
|
Anti-Bacterial Agents | 2 | 1989 | 7095 | 0.050 |
Why?
|
Radiography | 2 | 2009 | 6978 | 0.050 |
Why?
|
Labor, Obstetric | 1 | 2002 | 316 | 0.050 |
Why?
|
Data Collection | 2 | 2002 | 3317 | 0.050 |
Why?
|
Survival Rate | 4 | 2016 | 13206 | 0.050 |
Why?
|
Antibiotic Prophylaxis | 1 | 2005 | 628 | 0.050 |
Why?
|
Ventricular Fibrillation | 1 | 2002 | 534 | 0.050 |
Why?
|
Sex Distribution | 1 | 2005 | 2371 | 0.050 |
Why?
|
Thallium Radioisotopes | 1 | 1999 | 148 | 0.050 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1994 | 3375 | 0.050 |
Why?
|
Hospitals, Teaching | 1 | 1984 | 1153 | 0.040 |
Why?
|
Analysis of Variance | 2 | 1999 | 6501 | 0.040 |
Why?
|
Dipyridamole | 1 | 1999 | 154 | 0.040 |
Why?
|
Dobutamine | 1 | 1999 | 126 | 0.040 |
Why?
|
Acute Disease | 2 | 2008 | 7140 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 1 | 2006 | 34430 | 0.040 |
Why?
|
Hemorrhage | 3 | 2014 | 3279 | 0.040 |
Why?
|
Self Concept | 1 | 2005 | 1029 | 0.040 |
Why?
|
Benchmarking | 1 | 2005 | 927 | 0.040 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 1999 | 191 | 0.040 |
Why?
|
Schizophrenia | 1 | 1997 | 6702 | 0.040 |
Why?
|
Histamine H2 Antagonists | 1 | 2000 | 169 | 0.040 |
Why?
|
Synostosis | 1 | 1998 | 39 | 0.040 |
Why?
|
Nursing Homes | 1 | 2006 | 967 | 0.040 |
Why?
|
Needs Assessment | 1 | 2004 | 1147 | 0.040 |
Why?
|
Cities | 2 | 2014 | 498 | 0.040 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2007 | 3551 | 0.040 |
Why?
|
Comorbidity | 2 | 2013 | 10435 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2011 | 2558 | 0.040 |
Why?
|
Akathisia, Drug-Induced | 1 | 1997 | 68 | 0.040 |
Why?
|
Postoperative Period | 1 | 2003 | 1843 | 0.040 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2009 | 9004 | 0.040 |
Why?
|
Primary Prevention | 2 | 2013 | 1161 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2002 | 15199 | 0.040 |
Why?
|
Incidence | 3 | 2013 | 20731 | 0.040 |
Why?
|
Tachycardia, Ventricular | 2 | 2002 | 1214 | 0.040 |
Why?
|
|